Fulgent Genetics (NASDAQ:FLGT) and Progenity (NASDAQ:PROG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Insider & Institutional Ownership
59.3% of Fulgent Genetics shares are owned by institutional investors. 47.0% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Fulgent Genetics and Progenity’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Fulgent Genetics and Progenity’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fulgent Genetics||$32.53 million||17.58||-$410,000.00||$0.02||1,317.50|
Progenity has lower revenue, but higher earnings than Fulgent Genetics.
This is a breakdown of current ratings and recommmendations for Fulgent Genetics and Progenity, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fulgent Genetics presently has a consensus target price of $17.06, suggesting a potential downside of 35.26%. Progenity has a consensus target price of $13.75, suggesting a potential upside of 50.93%. Given Progenity’s stronger consensus rating and higher possible upside, analysts clearly believe Progenity is more favorable than Fulgent Genetics.
Fulgent Genetics beats Progenity on 5 of the 9 factors compared between the two stocks.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Progenity, Inc., a biotechnology company, provides complex molecular and specialized testing services to physicians, clinicians, and their patients in the United States. It offers testing services for common hereditary disorders, cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and Jewish genetic diseases; pan-ethnic carrier screening services; non-invasive prenatal, miscarriage, and pharmacogenetic testing services; and ovarian assessment reports for women. The company also provides pediatric testing services. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November, 2013. The company was incorporated in 2012 and is based in San Diego, California with a laboratory in Ann Arbor, Michigan. It has a bill payment location in Detroit, Michigan.
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.